These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20186876)

  • 1. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
    Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
    Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.
    Teitz-Tennenbaum S; Li Q; Davis MA; Wilder-Romans K; Hoff J; Li M; Chang AE
    J Immunother; 2009; 32(6):602-12. PubMed ID: 19483649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
    Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
    J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
    Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
    J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
    Salem ML; Díaz-Montero CM; Al-Khami AA; El-Naggar SA; Naga O; Montero AJ; Khafagy A; Cole DJ
    J Immunol; 2009 Feb; 182(4):2030-40. PubMed ID: 19201856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
    Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
    Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.
    Poehlein CH; Haley DP; Walker EB; Fox BA
    Eur J Immunol; 2009 Nov; 39(11):3121-33. PubMed ID: 19839008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells.
    Zecher D; Li Q; Oberbarnscheidt MH; Demetris AJ; Shlomchik WD; Rothstein DM; Lakkis FG
    J Immunol; 2010 Jun; 184(12):6649-57. PubMed ID: 20483732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
    Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.
    Yu P; Bamford RN; Waldmann TA
    Eur J Immunol; 2014 Nov; 44(11):3330-41. PubMed ID: 25142300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation.
    Johnson LD; Jameson SC
    J Immunol; 2010 May; 184(10):5604-11. PubMed ID: 20393139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
    Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
    Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
    Koike N; Pilon-Thomas S; Mulé JJ
    J Immunother; 2008 May; 31(4):402-12. PubMed ID: 18391755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
    Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
    Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.
    Cho HI; Reyes-Vargas E; Delgado JC; Celis E
    Cancer Res; 2012 Apr; 72(8):1986-95. PubMed ID: 22367213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antitumor immune responses in reconstituted lymphopenic hosts.
    Hu HM; Poehlein CH; Urba WJ; Fox BA
    Cancer Res; 2002 Jul; 62(14):3914-9. PubMed ID: 12124318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.